Menu
Clinical Experience
Protocol | Location | Clinical Phase | Indication | Completion Status |
---|---|---|---|---|
MLP-001 | China | Phase I | Healthy Volunteers | Completed |
WEX-US-001 | Canada / US | Phase I | PK study in Healthy Male Volunteers | Completed |
WEX-001 | Canada | Phase I | Healthy Volunteers | Completed |
WEX-002 | Canada | Phase I | Healthy Volunteers | Completed |
WEX-015 | Canada | Phase I | Healthy Volunteers | Completed |
MLP-002 | China | Phase IIa | Cancer Patients (Refractory pain) | Completed |
WEX-003 | Canada | Phase IIa | Cancer Patients (Refractory Pain) | Completed |
WEX-008 | Canada | Phase IIa | Cancer Patients (Refractory Pain) | Completed |
WEX-014 | Canada | Phase IIb | Cancer Patients (Refractory Pain) | Completed |
WEX-014OL | Canada | Phase IIb | Cancer Patients (Refractory Pain) | Completed |
TEC-006 | Canada/Australia/New Zealand | Phase III | Cancer Patients (Refractory Pain) | Completed |
TEC-006OL | Canada/Australia/New Zealand | Phase III | Cancer Patients (Refractory Pain) | Completed |
TTX-CINP-201-PK | United States | Phase I | PK Study in Healthy Volunteers | Completed |
TTX-CINP-201 | United States | Phase II | Chemotherapy-Induced Neuropathic Pain | Completed |
TTX-TQT-101 | United States | Phase I | Cardiovascular Effect of Tetrodotoxin in Healthy Volunteers | Completed |